## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -7.3% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($55.40)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Arcellx: Funded Into 2028 With Strong Clinical Data (NASDAQ:ACLX)**
- Source: Seeking Alpha | 20251217T130901 | Bullish | Relevance: 100%
- Arcellx (ACLX) is poised to disrupt the multiple myeloma cell therapy market with anito-cel, offering superior efficacy, safety, and scalable manufacturing. The company boasts a $576 million cash runway extending into 2028, significantly reducing dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's impressive 96% overall response rate (ORR), 74% complete response (CR/sCR), and clean safety profile, particularly its absence of neurotoxicity, set it apart from competitors like Carvykti.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($2.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.2% 5d) with bearish MACD, trend may be turning.
2. High short interest (15.2%, 7.7 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 10.6% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 242% YoY. Insider selling cluster ($2.5M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 15.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -2.0% to -7.3% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.3pp (needs >3.0% for momentum thesis). Underperforming sector by 7.2pp, stock-specific weakness. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram bearish (-0.51), momentum weakening. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -7.26% (CS: 2) | Weak |
| RSI_14 | 30.9 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 0.899x | Below |
| vs SMA50 | 0.789x | Below |
| vs SMA200 | 0.894x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $63.96
- **Stop Loss:** $55.40 (13.4% risk)
- **Target:** $72.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 140
- **Position Value:** $8,954.40
- **Portfolio %:** 8.95%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*